Related Experiment Video
Updated: Apr 17, 2026

Following in Real Time the Impact of Pneumococcal Virulence Factors in an Acute Mouse Pneumonia Model Using Bioluminescent Bacteria
Published on: February 23, 2014
Abstract:
In 2007, due to the number of invasive pneumococcal infections and resistance to antibiotics, Belgium introduced juvenile anti-pneumococcal vaccination, recommending the 7-valent conjugate vaccine which provides better immune protection and memory than the 23-valent one for adults. In 2011, due to the increase in non-vaccine serotypes, the decision was taken to replace the 7-valent vaccine with a conjugate 13-valent one. Henceforth, essentially high-risk adults are given a 13-valent vaccine followed 8 weeks later by a 23-valent one, with a 23-valent booster every 5 years.
Related Concept Videos
Pneumonia V: Nursing management and Prevention
The nurse must practice strict medical asepsis and adhere to infection control guidelines to minimize healthcare-associated infections.
Enhance airway patency
Position the patient correctly to facilitate drainage of the affected lung segments. Manual or mechanical percussion and vibration can also be employed....
Pneumonia III: Complications and Assessment
Pneumonia IV: Management
Bacterial Pneumonia Treatment
For bacterial pneumonia, antibiotics serve as the cornerstone of therapy. Initial treatment often begins with empirical antibiotics, tailored to the anticipated causative organism and adjusted based on culture results. Key antibiotic choices include:
Pneumonia I: Introduction
Pneumonia I: Introduction
Risk Factors
Various factors influence the likelihood of developing pneumonia. Age plays a crucial role, with infants, children under two, and individuals over 65 at increased risk due to their...
Atypical Pneumonia

